Notice Of The Settlement Of Patent Infringement Litigation Related To Lenvatinib In The U.S.
06/11/2025 23:31
Nov 7 (Reuters) - Eisai Co Ltd 4523.T: EISAI CO LTD - NOTICE OF THE SETTLEMENT OF PATENT INFRINGEMENT LITIGATION RELATED TO LENVATINIB IN THE U.S. Source text: ID:nTSwf904a3 Further company coverage: 4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China